30 likes | 180 Views
ARISTOTLE: Stroke or systemic embolism according to different risk scores Secondary analysis of randomized trial. Number Of patients. Apixaban. Warfarin. HR (95% CI). P value. CHADS 2 score 1. CHADS 2 score 2. CHADS 2 score ≥ 3. CHA 2 DS 2 VASc score 1.
E N D
ARISTOTLE: Strokeor systemicembolismaccording to different risk scoresSecondary analysis of randomized trial Number Of patients Apixaban Warfarin HR (95% CI) P value CHADS2 score 1 CHADS2 score 2 CHADS2 score ≥ 3 CHA2 DS2 VASc score 1 CHA2 DS2 VASc score 2 12 CHA2 DS2 VASc score ≥3 HAS-BLED Score 0-1 HAS-BLED Score 2 HAS-BLED Score ≥ 3 Overall Favoursapixaban Favourswarfarin LopesRD et al Lancet. 2012 Oct 1.
ARISTOTLE: Major bleedingaccording to different risk scores Secondary analysis of randomized trial Number Of patients Apixaban Warfarin HR (95% CI) P value CHADS2 score 1 CHADS2 score 2 CHADS2 score ≥ 3 CHA2 DS2 VASc score 1 CHA2 DS2 VASc score 2 CHA2 DS2 VASc score ≥3 HAS-BLED Score 0-1 HAS-BLED Score 2 HAS-BLED Score ≥ 3 Overall Favoursapixaban Favourswarfarin LopesRD et al Lancet. 2012 Oct 1.
ARISTOTLE: Intracranialbleedingaccording to different risk scores Secondary analysis of randomized trial Number Of patients Apixaban Warfarin HR (95% CI) P value CHADS2 score 1 CHADS2 score 2 CHADS2 score ≥ 3 CHA2 DS2 VASc score 1 CHA2 DS2 VASc score 2 CHA2 DS2 VASc score ≥3 HAS-BLED Score 0-1 HAS-BLED Score 2 HAS-BLED Score ≥ 3 Overall Favoursapixaban Favourswarfarin LopesRD et al Lancet. 2012 Oct 1.